MQS Management’s Neurocrine Biosciences NBIX Stock Holding History

MQS Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,471	Closed	-$326K	–	407
2026 Q1	$326K	Buy	2,471 +429	+21%	+$56.9K	0.22%	188
2025 Q4	$290K	Buy	+2,042	New	+$296K	0.17%	258
2024 Q4	–	Sell	-1,769	Closed	-$204K	–	254
2024 Q3	$204K	Sell	1,769 -1,103	-38%	-$151K	0.11%	371
2024 Q2	$395K	Sell	2,872 -1,126	-28%	-$154K	0.24%	167
2024 Q1	$551K	Buy	+3,998	New	+$546K	0.32%	102
2023 Q3	–	Sell	-3,024	Closed	-$285K	–	557
2023 Q2	$285K	Buy	3,024 +11	+0.4%	+$1.07K	0.19%	241
2023 Q1	$305K	Buy	+3,013	New	+$314K	0.2%	230

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MQS Management's NBIX Position: Q2 2026 in Review

MQS Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2,471 shares — an estimated $326K sold.

MQS Management first reported a position in NBIX in Q1 2023 and held it in 7 quarters. The position peaked at $551K in Q1 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

MQS Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
MQS Management sold 2,471 Neurocrine Biosciences shares in Q2 2026, an estimated $326K.
MQS Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 7 quarters.
MQS Management's Neurocrine Biosciences position peaked at $551K in Q1 2024.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MQS Management's 13F filing for Q2 2026, filed 7 Aug 2026.